Alla studier
RekryteringTerapeutisk utforskande (Fas II)Interventionell

A Phase 2 study to assess the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva in male and female paediatric and adult participants.

This research study is looking into a new medication called fidrisertib (also known as IPN60130) for people, both young and old, who have a rare condition called Fibrodysplasia Ossificans Progressiva (FOP). FOP causes extra bone to grow in soft tissues, which can be very painful and limit movement. The main goal is to find out if this new medicine can help slow down or stop this extra bone from forming, and if it can make flare-ups happen less often. Researchers will also be checking carefully to make sure the medicine is safe. Some people in the study will be given the actual medicine, while others will receive a dummy pill, called a placebo, to compare the effects.

Överblick

Status
Rekrytering
Fas
Terapeutisk utforskande (Fas II)
Sponsor
Clementia Pharmaceuticals Inc. An Ipsen Company
Inskrivningsmål
34
Starta
26 Apr 2024

Vad handlar denna studie om?

This study is called a 'Phase 2' trial. This means that the new medicine, fidrisertib, has already been tested in a small number of people and found to be generally safe. Now, we're looking to see if it actually works for people with Fibrodysplasia Ossificans Progressiva (FOP) and to understand the best dose to use. FOP is a very rare condition where muscles, tendons, and ligaments gradually turn into bone, which can cause pain and severe limitations in movement.

The main aim of this study is to see if fidrisertib can help reduce the amount of new bone that forms in people with FOP over a year. We'll be using special low-dose X-rays to measure any changes. We also want to see if the medicine can reduce how often people experience painful flare-ups and how long they last. Safety is always a top priority, so we'll be closely monitoring for any side effects from the medicine.

By comparing participants who receive fidrisertib with those who receive a dummy pill (placebo), we can get a clearer picture of the medicine's effects. This research is incredibly important because it could lead to new ways to manage FOP and improve the lives of those living with this challenging condition.

Viktiga punkter

  • This study tests a new oral medicine (fidrisertib) for Fibrodysplasia Ossificans Progressiva (FOP).
  • It aims to see if the medicine can reduce new bone growth and lessen flare-ups.
  • Participants will receive either fidrisertib or a placebo (dummy pill).
  • The study involves regular clinic visits, physical exams, blood tests, and X-rays over 12 months.
  • It's a Phase 2 study, meaning the medicine's effectiveness and safety are being further investigated.
  • Participants must be 18 years or older with an FOP diagnosis.

Vem kan vara berättigad?

This study is open to both men and women, ranging from 18 years old up to any age, who have been diagnosed with Fibrodysplasia Ossificans Progressiva (FOP). The study team will need to review your medical history to make sure that taking part would be safe and appropriate for you.

Because this is a research study and safety is key, there may be certain medical conditions or medications that would prevent someone from joining. For example, conditions that might interact with the study drug, or other health issues that could make it difficult to accurately measure the drug's effects, might mean someone isn't eligible.

If you're interested, the best first step is to talk to your doctor. They can help you understand if your specific health situation aligns with the study's requirements and can also discuss any questions you might have about FOP treatments in general.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. I have been diagnosed with Fibrodysplasia Ossificans Progressiva (FOP).
  2. Jag är 18 år gammal eller äldre.
  3. I am able to visit the clinic for regular check-ups and tests.
  4. I am willing to take a study capsule every day for 12 months.
  5. I am willing to undergo regular X-rays and have blood/urine samples taken.
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part in this study, you would be asked to take a capsule by mouth every day. You'll either receive the active study medicine, fidrisertib, or a placebo (a dummy pill that looks just like the study medicine but contains no active drug). You won't know which one you're taking, and neither will the study team at first. This helps us get accurate results.

Throughout the study, you'll have regular visits to the clinic for various checks. These will include physical exams, checking your vital signs (like blood pressure and heart rate), measuring your weight and height, and taking blood and urine samples for lab tests. You'll also have special low-dose X-ray scans (called WBCT) to look at any changes in bone growth. For women who could become pregnant, regular pregnancy tests will be part of the routine. We'll also ask about any other medicines you're taking and if you've had any new health problems or flare-ups. The study will last for a total of 12 months.

Potentiella risker och fördelar

Taking part in any medical study has potential benefits and risks. A potential benefit of this study is that fidrisertib might help to slow down new bone growth and reduce flare-ups associated with FOP. This could potentially improve your quality of life. However, there's no guarantee you'll receive the active medicine or that it will help you. Like all medicines, fidrisertib could cause side effects, which might be mild or more serious. The study team will explain all known potential risks in detail before you decide to join. Remember, taking part in this study is completely voluntary, and you are free to withdraw at any time without giving a reason, and it won't affect your usual medical care.

Platser (8)

Vissa platsangivelser är ungefärliga. Vi arbetar på att förbättra detta — vänligen kontrollera med testteamet innan du reser.
  • —
    Obekräftad
    Sverige
  • —
    Obekräftad
    Tyskland
  • —
    Obekräftad
    Frankrike
  • —
    Obekräftad
    Nederländerna
  • —
    Obekräftad
    Spanien
  • —
    Obekräftad
    Belgien
  • —
    Obekräftad
    Italien
  • —
    Obekräftad
    Portugal

Vanliga frågor

What is Fibrodysplasia Ossificans Progressiva (FOP)?

FOP is a very rare genetic disorder where soft tissues, like muscles and tendons, gradually turn into bone, causing pain and restricted movement.

Vad är en 'placebo'?

Ett placebo är ett sockerpiller som ser exakt ut som studiemedicinen men inte innehåller något aktivt läkemedel. Det hjälper forskare att jämföra effekterna av den riktiga medicinen.

Kommer jag att veta om jag får den riktiga medicinen eller placebo?

No, neither you nor the study team will know at first. This is called 'blinding' and helps ensure the study results are as fair and accurate as possible.

Hur länge behöver jag vara med i studien?

If you decide to join, you will be part of the study for about 12 months, which includes regular check-ups and tests.

What are flare-ups?

In FOP, flare-ups are episodes where a sudden new area of inflammation can appear, often leading to rapid new bone formation and pain.

Hur du får reda på mer

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "A Phase 2 study to assess the efficacy and safety of 2 dosag…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.